These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 21661438)
1. GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. Milandri C; Polico R; Garcea D; Passardi A; Gardini A; Romeo A; Scarpi E; Rosetti P; Ridolfi L; La Barba G; Ricci M; Amadori D Hepatogastroenterology; 2011; 58(106):599-603. PubMed ID: 21661438 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ; J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661 [TBL] [Abstract][Full Text] [Related]
3. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287 [TBL] [Abstract][Full Text] [Related]
5. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Passardi A; Scarpi E; Neri E; Parisi E; Ghigi G; Ercolani G; Gardini A; La Barba G; Pagan F; Casadei-Gardini A; Valgiusti M; Ferroni F; Frassineti GL; Romeo A Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31086093 [TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Demols A; Peeters M; Polus M; Marechal R; Gay F; Monsaert E; Hendlisz A; Van Laethem JL Br J Cancer; 2006 Feb; 94(4):481-5. PubMed ID: 16434988 [TBL] [Abstract][Full Text] [Related]
8. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. Hunter KU; Feng FY; Griffith KA; Francis IR; Lawrence TS; Desai S; Murphy JD; Zalupski MM; Ben-Josef E Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):921-6. PubMed ID: 22208966 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Li J; Merl M; Lee MX; Kaley K; Saif MW Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915 [TBL] [Abstract][Full Text] [Related]
10. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Sahora K; Kuehrer I; Eisenhut A; Akan B; Koellblinger C; Goetzinger P; Teleky B; Jakesz R; Peck-Radosavljevic M; Ba'ssalamah A; Zielinski C; Gnant M Surgery; 2011 Mar; 149(3):311-20. PubMed ID: 20817204 [TBL] [Abstract][Full Text] [Related]
11. Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies. Passardi A; Rapposelli IG; Scarpi E; Sullo FG; Bartolini G; Neri E; Ghigi G; Tontini L; Ercolani G; Monti M; Ruscelli S; Matteucci L; Valgiusti M; Frassineti GL; Romeo A Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439866 [TBL] [Abstract][Full Text] [Related]
12. Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, randomized controlled trial comparing with intravenous chemotherapy. Huang C; Cheng CS; Shen Y; Chen H; Lin J; Hua Y; Feng L; Wu C; Wang P; Chen Z; Meng Z BMC Cancer; 2024 Aug; 24(1):941. PubMed ID: 39095759 [TBL] [Abstract][Full Text] [Related]
13. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Fogelman D; Jafari M; Varadhachary GR; Xiong H; Bullock S; Ozer H; Lin E; Morris J; Cunningham P; Bennett B; Abbruzzese JL; Wolff RA Cancer Chemother Pharmacol; 2011 Dec; 68(6):1431-8. PubMed ID: 21479635 [TBL] [Abstract][Full Text] [Related]
14. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537 [TBL] [Abstract][Full Text] [Related]
15. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. Moureau-Zabotto L; Phélip JM; Afchain P; Mineur L; André T; Vendrely V; Lledo G; Dupuis O; Huguet F; Touboul E; Balosso J; Louvet C J Clin Oncol; 2008 Mar; 26(7):1080-5. PubMed ID: 18309942 [TBL] [Abstract][Full Text] [Related]
16. Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. Gunnlaugsson A; Anderson H; Lind P; Glimelius B; Johnsson A Radiother Oncol; 2010 Jun; 95(3):292-7. PubMed ID: 20451275 [TBL] [Abstract][Full Text] [Related]
17. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367 [TBL] [Abstract][Full Text] [Related]
18. [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer]. Xie DR; Liang HL; Yang Q; Guo SS; Jiang ZM Ai Zheng; 2007 Aug; 26(8):895-9. PubMed ID: 17697555 [TBL] [Abstract][Full Text] [Related]
19. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer. Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. Wei W; Wu P; Li L; Zhang ZH Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]